Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists

CME Available: https://auau.auanet.org/node/42040

After participating in this CME activity, participants will be able to:

1. Describe the multimodal treatment approach for MIBC, including surgery, radiation therapy, and chemotherapy.

2. Analyze the role of neoadjuvant and adjuvant therapies, including chemotherapy, immunotherapy, and antibody drug conjugates, in improving patient outcomes.

3. Utilize knowledge of checkpoint inhibitors and antibody drug conjugates with their mechanisms of action to interpret the role of immunotherapy in the treatment of metastatic urothelial carcinoma.

4. Examine ongoing clinical trials and emerging treatments that are shaping the future of metastatic urothelial carcinoma management.

5. Employ appropriate patient and family education strategies regarding MIBC and metastatic urothelial carcinoma, treatment options, and expected outcomes.

Acknowledgements

Support provided by an independent educational grant from:

Astellas and Pfizer, Inc.

Complex Cases in Kidney Stone Disease

CME Available: https://auau.auanet.org/node/41889

At the conclusion of this activity, participants will be able to:

1. Describe the pathophysiology, genetic basis, and clinical presentation of Primary Hyperoxaluria Type 1.

2. Analyze the unique considerations and challenges in evaluating kidney stones in pediatric patients.

3. Utilize the results of 24-hour urine testing to guide dietary and pharmacologic interventions for stone prevention.

4. Recognize the indications for genetic testing in patients with kidney stones and utilize the results to inform diagnosis and treatment.

5. Employ appropriate patient management and family counseling strategies in consideration of the impact of genetic testing results.

6. Properly refer patients with kidney stone disease to a nephrologist when warranted.

ACKNOWLEDGEMENTS:

Support provided by an independent educational grant from: 

Alnylam Pharmaceuticals, Inc.

Now in its 43rd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.

For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update24

AUA2024: Journal of Urology Lecture: Empowering Communities: Fostering Prostate Cancer Awareness and Resilience Among Men of Color

Presenter: Quoc-Dien Trinh, MD, MBA

AUA2024: Ramon Guiteras Lecture: Modern Innovation: Promise or Peril?

Presenter: Craig Niederberger, MD, FACS

AUA Leadership and Business Podcast: Urology Practice Manage - Overcoming Operational Challenges

This episode is brought to you by the AUA Leadership and Business Podcast, where urologic professionals experience the practical application of business acumen essential to successfully navigating today’s rapidly changing business environment! Subscribe today via your favorite podcast app.

Focal Therapy Options for Prostate Cancer

AUA Urology Core Curriculum: auau.auanet.org/core

Host: Jay D. Raman, MD, FACS, FRCS(Glasg)

Guest: Ruben Olivares, MD

Outline:

Segment 1: Why Focal Therapy?

Segment 2: Patient selection for Focal Therapy

Segment 3: Review of Existing Focal Therapy Modalities

Segment 4: How to Build a Successful Focal Therapy Program

Hereditary Kidney Cancer Syndromes

CME Available: https://auau.auanet.org/node/41772

ACKNOWLEDGEMENTS:

Support provided by an independent educational grant from: 

Merck & Co., Inc. 

LEARNING OBJECTIVES:

At the conclusion of this activity, participants should be able to:

1. Select patients who should undergo genetic testing to identify hereditary kidney cancer syndromes based on appropriate criteria, including family history and clinical presentation.

2. Implement strategies to address ethical concerns related to genetic testing, such as patient consent, confidentiality, and the potential impact on family members.

3. Discuss VHL syndrome, including its genetic basis, inheritance pattern, and associated tumors.

4. Properly diagnose and manage VHL syndrome in clinical practice based on knowledge of novel therapeutic strategies.

5. Utilize a multidisciplinary approach consisting of urologists, oncologists, geneticists and nephrologists when managing hereditary kidney cancer syndromes.

Prostate Cancer Update (2024): Expert Guidance for Urologists

CME Available: https://auau.auanet.org/node/41868

Acknowledgements

Support provided by independent educational grants from:

Astellas

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Learning Objectives

At the conclusion of this activity, the learner will:

1. Align their practice with current AUA Guidelines (and recent amendments) pertaining to Screening, Diagnosis, and Management of Prostate Cancer.

2. Determine appropriate use of biomarker testing as it relates to diagnosis and therapy.

3. Analyze the role of imaging and types of imaging that aid in staging patients with prostate cancer.

4. Implement appropriate treatment paradigms for metastatic prostate cancer including treatment intensification.

5. Discuss the role of genetic and molecular profiling in the personalization of prostate cancer treatment plans.

Treatment Intensification in Metastatic HSPC

CME Available: https://auau.auanet.org/node/41733

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology. 

2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks. 

3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.